M&A M&A
Aurobindo Pharma’s arm ups stake in JV with Chinese firm Luoxin for $5.12 M
Source Luoxin Aurovitas (opens in a new tab)Business Line (opens in a new tab)BSE Announcement (opens in a new tab)
Hyderabad-based Helix Healthcare B.V., a wholly-owned subsidiary of Aurobindo Pharma, will acquire an additional 20% stake in Shandong, China-based Luoxin Aurovitas , its joint venture with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., China, for USD 5.12 million. This transaction will increase Helix's stake in the joint venture to 50%.The transaction also includes a provision for Helix to acquire the remaining 50% stake in the joint venture by December 2029 for USD 18.86 million.Luoxin Aurovitas recorded a turnover of USD 2.34 million in the 2024-25 fiscal year. Its net worth stood at USD 15.29 million as of September 30, 2025.